Pre-Operative, Single-Dose Ipilimumab and/or Cryoablation in Early Stage/Resectable Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Breast CancerInvasive Adenocarcinoma of the Breast
Interventions
PROCEDURE

Cryoablation

"OncCore Biopsy (+ Cryo) Date\*~* Pre- and post- cryo MRI~* Core biopsy x ≥3~* Cryoablation Optional pre-surgery MRI day prior or day of Mastectomy Date\* Safety assessment 30 (+/-10) days after surgery research bloods 30 (+/-10) days after surgery.\*"

BIOLOGICAL

Ipilimumab

"Ipilimumab Appt. with Med Onc Ipilimumab administered Core Biopsy Date\*~* MRI~* Core biopsy x ≥3 Optional pre-surgery MRI biopsy prior or day of Mastectomy Date\* Safety assessment 2-3 weeks post-mastectomy (co-ordinated with off-study surgery follow-up appt if feasible) and then every 2-3 weeks thereafter until at least 12 weeks post ipilimumab date. # Research bloods 30 (+/-10) days after surgery."

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT01502592 - Pre-Operative, Single-Dose Ipilimumab and/or Cryoablation in Early Stage/Resectable Breast Cancer | Biotech Hunter | Biotech Hunter